Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib with Carboplatin and Paclitaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer
NCT00494182Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2007
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2007; status: active, not recruiting.
02
Drugs
sorafenib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00494182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00494182.